Beyond IGF-1 mediated signaling, prostate cancer progression is strongly supported by activation of the phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and mechanistic target of rapamycin (mTOR) pathway, a major pro-survival axis frequently upregulated in advanced disease. Here, MTOR is linked to prostate carcinoma.